EGFR and prostate carcinoma: In addition to the overall preferences for targeting prostate cancer‐related proteins, the screened drugs also targeted the epidermal growth factor receptor (EGFR) signaling pathway, protein degradation, DNA repair, and cell cycle‐related proteins.